Compare Bristol-Myers Squibb Co (BMY) vs YieldMax COIN Option Income Strategy ETF (CONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs YieldMax COIN Option Income Strategy ETF — how do they compare? Bristol-Myers Squibb Co trades at $59.01 (market cap $116.30B), while YieldMax COIN Option Income Strategy ETF trades at $20.04. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while YieldMax COIN Option Income Strategy ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| BMY | CONY | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $62.37 | $103.20 |
52-Week Low | $42.60 | $18.43 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
CONY trades at $19.46, down 0.87% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid consistent weekly dividends, with recent payouts ranging from $0.24 to $0.56 per share. Key support lies at $19, with resistance at $20. Recent news highlights YieldMax's weekly distribution announcements, but some articles express concern over the ETF's long-term performance despite its high yield.
The outlook for CONY hinges on its ability to sustain high distributions through options strategies on Coinbase stock. Risks include the underlying volatility of Coinbase and the potential for distribution cuts if option income declines. Investors should weigh the attractive yield against the fund's bearish price trend and dependence on a single stock's options market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →
